High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future?
Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast cancer is the second leading cause of cancer-related death in women, it is clear that existing therapy fails a large number of patients. Recently, a number of novel strategies have been developed in attempts to improve survival. These include agents used at very high dose requiring stem cell support. High-dose chemotherapy (HDC) with hematopoietic stem cell transplantation (HSCT), most frequently in the form of peripheral blood progenitor cell transplantation (PBPCT), is an highly active treatment approach in appropriate patients and the current data relating to this modality will be reviewed here. This article will attempt to place the recent randomized studies in perspective, to highlight the strengths and limitations of the data, and to offer some thoughts on future directions for the field.
Baynes
R D
RD
Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, MI 48201, USA.
Dansey
R D
RD
Klein
J L
JL
Hamm
C
C
Campbell
M
M
Abella
E
E
Peters
W P
WP
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans
D000970:Antineoplastic Agents